肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2015年
5期
342-344
,共3页
放射疗法%酪氨酸激酶抑制剂%表皮生长因子受体%癌,非小细胞肺%脑转移
放射療法%酪氨痠激酶抑製劑%錶皮生長因子受體%癌,非小細胞肺%腦轉移
방사요법%락안산격매억제제%표피생장인자수체%암,비소세포폐%뇌전이
Radiotherapy%Tyrosine kinase inhibitors%Epidermal growth factor receptor driven mutation%Cancer,non-small cell lung%Brain metastasis
目的 探讨放疗联合酪氨酸激酶抑制剂(TKI)治疗表皮生长因子受体(EGFR)驱动突变的非小细胞肺癌(NSCLC)脑转移的临床价值和安全性.方法 回顾性分析21例EGFR驱动突变的NSCLC脑转移患者的临床资料,其中放疗联合TKI治疗10例(观察组),单纯放疗1 1例(对照组).在放疗结束后4周复查脑磁共振成像(MRI),观察肿瘤大小,评价近期疗效,以后每3个月一次进行临床疗效评价,统计中位总生存时间.结果 观察组客观缓解8例,疾病控制9例,中位总生存时间11.2个月;对照组11例,客观缓解4例;疾病控制8例,中位总生存时间6.4个月.观察组的不良反应主要有恶心、腹泻、皮疹,都可以耐受.结论 放疗联合TKI治疗对EGFR驱动突变的NSCLC脑转移具有很好的疗效、较高的安全性,可以作为此类患者的一种优先选择的治疗模式.
目的 探討放療聯閤酪氨痠激酶抑製劑(TKI)治療錶皮生長因子受體(EGFR)驅動突變的非小細胞肺癌(NSCLC)腦轉移的臨床價值和安全性.方法 迴顧性分析21例EGFR驅動突變的NSCLC腦轉移患者的臨床資料,其中放療聯閤TKI治療10例(觀察組),單純放療1 1例(對照組).在放療結束後4週複查腦磁共振成像(MRI),觀察腫瘤大小,評價近期療效,以後每3箇月一次進行臨床療效評價,統計中位總生存時間.結果 觀察組客觀緩解8例,疾病控製9例,中位總生存時間11.2箇月;對照組11例,客觀緩解4例;疾病控製8例,中位總生存時間6.4箇月.觀察組的不良反應主要有噁心、腹瀉、皮疹,都可以耐受.結論 放療聯閤TKI治療對EGFR驅動突變的NSCLC腦轉移具有很好的療效、較高的安全性,可以作為此類患者的一種優先選擇的治療模式.
목적 탐토방료연합락안산격매억제제(TKI)치료표피생장인자수체(EGFR)구동돌변적비소세포폐암(NSCLC)뇌전이적림상개치화안전성.방법 회고성분석21례EGFR구동돌변적NSCLC뇌전이환자적림상자료,기중방료연합TKI치료10례(관찰조),단순방료1 1례(대조조).재방료결속후4주복사뇌자공진성상(MRI),관찰종류대소,평개근기료효,이후매3개월일차진행림상료효평개,통계중위총생존시간.결과 관찰조객관완해8례,질병공제9례,중위총생존시간11.2개월;대조조11례,객관완해4례;질병공제8례,중위총생존시간6.4개월.관찰조적불량반응주요유악심、복사、피진,도가이내수.결론 방료연합TKI치료대EGFR구동돌변적NSCLC뇌전이구유흔호적료효、교고적안전성,가이작위차류환자적일충우선선택적치료모식.
Objective To evaluate the clinical value and safety of radiotherapy combined with tyrosine kinase inhibitors (TKI) in non-small cell lung cancer (NSCLC) with brain metastasis driven by epidermal growth factor receptor (EGFR) mutation.Methods A retrospective cohort of 21 non-small cell lung cancer (NSCLC) patients with EGFR mutation-driven brain metastasis was recruited.10 patients (treatment group) were randomly selected for radiotherapy combined with TKI treatment,and 11 patients (control group) were treated with radiotherapy.Tumor size was measured and clinical efficacy was evaluated by MRI in the four weeks after radiotherapy.Since then,a clinical response was evaluated every three months until disease progression,and the median overall survival time was calculated.Results The objective remission was 8 cases in treatment group and 4 cases in control group.The disease control was 9 cases in treatment group and 8 cases in control group.The median overall survival time of treatment and control groups was 11.2 months and 6.4 months,respectively.Adverse reactions in treatment group mainly contained nausea,diarrhea and rash,which all were tolerated.Conclusion Radiotherapy combined with TKI is superior to radiotherapy alone in effect and safety for treatment of NSCLC with EGFR mutation-driven brain metastasis.
